Similar articles

• Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.

  Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 Jun 1;61(21):394-5. MMWR Morb Mortal Wkly Rep. 2012. PMID: 22647745
• Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.

  Reinert RR, Paradiso P, Fritzell B. Reinert RR, et al. Expert Rev Vaccines. 2010 Mar;9(3):229-36. doi: 10.1586/erv.10.6. Expert Rev Vaccines. 2010. PMID: 20218848 Review. No abstract available.
• Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.

  Rose M, Zielen S. Rose M, et al. Expert Rev Vaccines. 2009 Oct;8(10):1351-64. doi: 10.1586/erv.09.78. Expert Rev Vaccines. 2009. PMID: 19803758 Review.
• Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9. MMWR Morb Mortal Wkly Rep. 2012. PMID: 23051612
• US approves Prevnar pneumonia vaccine for adults.

  [No authors listed] [No authors listed] Clin Infect Dis. 2012 Mar;54(6):ii. Clin Infect Dis. 2012. PMID: 22462087 No abstract available.